ClinicalTrials.Veeva

Menu

Epidemiology of Congenital Heart Disease in France (EPIDEMIO-CHD)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Completed

Conditions

Congenital Heart Disease

Study type

Observational

Funder types

Other

Identifiers

NCT04740177
RECHMPL20_0119

Details and patient eligibility

About

Congenital heart disease (CHD) is the leading cause of birth defects, with an incidence of 0.8%. Since the 1980s, France has been a pioneer in neonatal CHD surgery (Pr. Fontan, Pr. Lecomte, Pr. Serraf, etc.), in prenatal diagnosis, and in interventional cardiac catheterization.

Actually, first children operated for complex CHD have reached adulthood and a new epidemiology of CHD is emerging. Currently, one of the public health challenges is the need to maintain appropriate follow-up and to avoid disruption of care during the transition from adolescence to adulthood. Thus, the national health authorities (DGOS) recently certified a national network of expert centers for complex CHD (M3C).

In addition, under the leadership of the French Society of Cardiology, the sub-specialty of Pediatric and Congenital Cardiology has been recognized.

However, while North American and North European countries have published their updated data on the main indicators of CHD morbidity and mortality, no study has reported epidemiology of CHD in France.

Currently, available data are approximate, estimating that 200,000 children and 250,000 adults would be living in France with a CHD. Nevertheless, no information is available on hospitalizations, type of CHD, their follow-up, possible disruption in care, and morbidity and mortality in patients with CHD in France. This epidemiological study will use the national health insurance hospital database to answer these questions.

Full description

Retrospective epidemiological study based on the national health insurance hospital database from 2010 to 2020 (10 years):

Main objective:

• To assess the prevalence of patients with CHD hospitalized in France over 10 years.

Secondary objectives: asess over the same period:

  • Overall mortality rate according to the CHD classification and the geographic area
  • Overall morbidity rate, according to the CHD classification and the geographic area
  • Overall cardiac surgery-related mortality rate (cardiac surgery and other surgery), according to the CHD classification (adjusted for the severity of the CHD and the surgical procedure) and to geographic area
  • Overall cardiac catheter-related mortality rate, according to the CHD classification (adjusted for the severity of the CHD and the catheterization procedure) and to geographic area
  • CHD follow-up within and outside the national M3C network
  • Periods of loss of cardiological follow-up (within or outside the M3C network, in hospital or in town)
  • Obstetrical data for women (parity, pregnancy)
  • The existence of a prenatal diagnosis (yes / no and the term of pregnancy at the time of diagnosis of CHD)

Enrollment

450,000 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient (of any age) with a CHD as defined by the international ACC-CHD classification and listed in the ICD10 classification, hospitalized from 01/01/2010 to 12/31/2019 in a French tertiary care hospital from the M3C network.

Exclusion criteria

  • Patient with non-malformative genetic heart disease (cardiomyopathy, hereditary rhythmic disease).

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems